Novo Nordisk, the manufacturer of both, recently shared that CagriSema may lead to 10 percent more weight loss than Wegovy.

NYSE:NVO) Shareholders that lost money on Novo Nordisk A/S(NVO) should contact Levi & Korsinsky about Securities Fraud ...

Topline data were announced from a phase 3 trial evaluating CagriSema in overweight or obese patients without type 2 diabetes.

Two recent disappointing clinical trials of highly-anticipated weight-loss drugs have made it clear that it is too early to ...

REDEFINE 1 is a 68-week efficacy and safety trial investigating subcutaneous CagriSema (a fixed dose combination of cagrilintide 2.4 mg and semaglutide 2.4 mg) compared to the individual ...

Novo Nordisk's shares plummeted due to disappointing trial results for CagriSema, with patients achieving only 22.7% weight ...

Given its low valuation and the seeming overreaction in the markets to the recent trial results, this is a stock that could ...

In a new study, an experimental obesity drug from Novo Nordisk called CagriSema allowed people to lose more than 20 percent of their body weight, on average, a result that caused the Danish ...

In a phase 3 clinical trial investigating the usefulness of its anti-obesity drug candidate CagriSema, after being injected weekly for 68 weeks, patients lost 22.7% of their weight on average.

Novo Nordisk, the largest European company by market capitalization, has achieved worse than expected results for its new ...

CagriSema-treated patients achieved superior weight loss compared with those who received cagrilintide 2.4mg, semaglutide 2.4mg or placebo. Topline data were announced from a phase 3 trial ...